| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Molecular and Cellular Oncology (R.K.V., S.B., R.K.) and Department of Pathology (R.R.B.), The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030; and Center for Biotechnology (J.-Å.G.), Karolinska Institute, Novum, S-14157 Huddinge, Sweden
Address all correspondence and requests for reprints to: Ratna K. Vadlamudi, Department of Genetics, Stanley S. Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, Louisiana 70005. E-mail: rvadla{at}LSUHSC.edu; or Rakesh Kumar, Department of Molecular and Cellular Oncology, The University of Texas M. D. Anderson Cancer Center, Box 108, 1515 Holcombe Boulevard, Houston, Texas 77030. E-mail: rkumar{at}mdanderson.org.
Proline-, glutamic acid-, and leucine-rich protein-1)PELP1/MNAR [modulator of nongenomic activity of estrogen receptor (ER)], a novel coregulatory protein, modulates genomic as well as nongenomic activity of ERs. We characterized the expression and localization of PELP1 in both benign and cancerous endometrium. Our results suggest that PELP1 is expressed in all stages of endometrium; however, this protein exhibits distinct localization depending on the phase. PELP1 is expressed in both the stroma and epithelial cells. Using the Ishikawa endometrial cancer model cell line and ER subtype-specific ligands, we found that PELP1 functionally interacts with both ER
and ERß and enhances their transcriptional responses. However, in endometrial cancer cells, endogenous PELP1 is also required for optimal ligand-mediated transcription and proliferation responses. PELP1 promoted a tamoxifen-mediated agonistic action in endometrial, but not in breast cancer cells. PELP1 expression and localization are widely deregulated in endometrial cancers. In addition, PELP1 and ERß were localized predominantly in the cytoplasm of high-grade endometrial tumors. Our results suggest that PELP1 plays an essential role in the proliferation of cancerous endometrial cells.
This article has been cited by other articles:
![]() |
R. Kumar, H. Zhang, C. Holm, R. K. Vadlamudi, G. Landberg, and S. K. Rayala Extranuclear Coactivator Signaling Confers Insensitivity to Tamoxifen Clin. Cancer Res., June 15, 2009; 15(12): 4123 - 4130. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Dimple, S. S. Nair, R. Rajhans, P. R. Pitcheswara, J. Liu, S. Balasenthil, X.-F. Le, M. E. Burow, N. Auersperg, R. R. Tekmal, et al. Role of PELP1/MNAR Signaling in Ovarian Tumorigenesis Cancer Res., June 15, 2008; 68(12): 4902 - 4909. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. K. Nagpal, S. Nair, D. Chakravarty, R. Rajhans, S. Pothana, D. W. Brann, R. R. Tekmal, and R. K. Vadlamudi Growth Factor Regulation of Estrogen Receptor Coregulator PELP1 Functions via Protein Kinase A Pathway Mol. Cancer Res., May 1, 2008; 6(5): 851 - 861. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Rajhans, H. B. Nair, S. S. Nair, V. Cortez, K. Ikuko, N. B. Kirma, D. Zhou, A. E. Holden, D. W Brann, S. Chen, et al. Modulation of in Situ Estrogen Synthesis by Proline-, Glutamic Acid-, and Leucine-Rich Protein-1: Potential Estrogen Receptor Autocrine Signaling Loop in Breast Cancer Cells Mol. Endocrinol., March 1, 2008; 22(3): 649 - 664. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Rajhans, S. Nair, A. H. Holden, R. Kumar, R. R. Tekmal, and R. K. Vadlamudi Oncogenic Potential of the Nuclear Receptor Coregulator Proline-, Glutamic Acid-, Leucine-Rich Protein 1/Modulator of the Nongenomic Actions of the Estrogen Receptor Cancer Res., June 1, 2007; 67(11): 5505 - 5512. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. S. Nair, Z. Guo, J. M. Mueller, S. Koochekpour, Y. Qiu, R. R. Tekmal, R. Schule, H.-J. Kung, R. Kumar, and R. K. Vadlamudi Proline-, Glutamic Acid-, and Leucine-Rich Protein-1/Modulator of Nongenomic Activity of Estrogen Receptor Enhances Androgen Receptor Functions through LIM-Only Coactivator, Four-and-a-Half LIM-Only Protein 2 Mol. Endocrinol., March 1, 2007; 21(3): 613 - 624. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Ohshiro, S. K. Rayala, M. D. Williams, R. Kumar, and A. K. El-Naggar Biological Role of Estrogen Receptor {beta} in Salivary Gland Adenocarcinoma Cells. Clin. Cancer Res., October 15, 2006; 12(20): 5994 - 5999. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. E. Gururaj, R. R. Singh, S. K. Rayala, C. Holm, P. den Hollander, H. Zhang, S. Balasenthil, A. H. Talukder, G. Landberg, and R. Kumar MTA1, a transcriptional activator of breast cancer amplified sequence 3 PNAS, April 25, 2006; 103(17): 6670 - 6675. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. K. Rayala, P. d. Hollander, S. Balasenthil, P. R. Molli, A. J. Bean, R. K. Vadlamudi, R.-A. Wang, and R. Kumar Hepatocyte Growth Factor-regulated Tyrosine Kinase Substrate (HRS) Interacts with PELP1 and Activates MAPK J. Biol. Chem., February 17, 2006; 281(7): 4395 - 4403. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. K. Rayala, J. Mascarenhas, R. K. Vadlamudi, and R. Kumar Altered localization of a coactivator sensitizes breast cancer cells to tumor necrosis factor-induced apoptosis. Mol. Cancer Ther., February 1, 2006; 5(2): 230 - 237. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. E. Gururaj, S. K. Rayala, R. K. Vadlamudi, and R. Kumar Novel Mechanisms of Resistance to Endocrine Therapy: Genomic and Nongenomic Considerations Clin. Cancer Res., February 1, 2006; 12(3): 1001s - 1007s. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. M. Khan, M. Hadman, C. Wakade, L. M. De Sevilla, K. M. Dhandapani, V. B. Mahesh, R. K. Vadlamudi, and D. W. Brann Cloning, Expression, and Localization of MNAR/PELP1 in Rodent Brain: Colocalization in Estrogen Receptor-{alpha}- But Not in Gonadotropin-Releasing Hormone-Positive Neurons Endocrinology, December 1, 2005; 146(12): 5215 - 5227. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. K. Vadlamudi, B. Manavathi, S. Balasenthil, S. S. Nair, Z. Yang, A. A. Sahin, and R. Kumar Functional Implications of Altered Subcellular Localization of PELP1 in Breast Cancer Cells Cancer Res., September 1, 2005; 65(17): 7724 - 7732. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Manavathi, S. S. Nair, R.-A. Wang, R. Kumar, and R. K. Vadlamudi Proline-, Glutamic Acid-, and Leucine-Rich Protein-1 Is Essential in Growth Factor Regulation of Signal Transducers and Activators of Transcription 3 Activation Cancer Res., July 1, 2005; 65(13): 5571 - 5577. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |